


PHARMACEUTICAL 2022



Salarius Pharmaceuticals Inc. Rank 183 of 475





PHARMACEUTICAL 2022



Salarius Pharmaceuticals Inc. Rank 183 of 475

The relative strengths and weaknesses of Salarius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Salarius Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Salarius Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is -43%, being 233% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	30,164
Cost of Goods Sold	0
Intangible Assets	8,866
Liabilities, Current	1,543
Liabilities, Non-Current	0
Other Assets	1,796
Other Compr. Net Income	0
Other Expenses	-45
Other Liabilities	568
Other Net Income	0
Property and Equipment	7.9
Research and Development	8,549
Revenues	1,840
Selling, General and Administrative Expense	6,105

Output Variable	Value in 1000 USD
Assets	40,834
Liabilities	2,111
Expenses	14,608
Stockholders Equity	38,723
Net Income	-12,768
Comprehensive Net Income	-12,768
Economic Capital Ratio	-43%